ReviewCancers2025
Desmoid Tumors-Experience from a Referral Center, Part 1: Multidisciplinary Review and Practical Recommendations.
Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- When Histology Is Unknown: Surgical Decision-Making in Small Bowel Tumors-From Preoperative Imaging to Intraoperative Findings: A Narrative Review.Journal of clinical medicine · 2026Review
- Abnormal Presentation of an Intra-abdominal Desmoid Tumor in a Young, Healthy Male: A Case Report.Cureus · 2026Article
- Real-World Characterization and Treatment Patterns of Patients with Desmoid Tumors at an Academic Center in the United States.Cancer research communications · 2026Article
- The Health-Related Quality of Life of German Desmoid Patients: Results from the PROSa-DES and PROSa Study.Cancers · 2026Article
- Experience of a Referral Center with Desmoid Tumors, Part 2: A Retrospective Analysis of 109 Cases.Cancers · 2026Article
- Cryoablation as a downsizing strategy enabling R0 resection in a giant mediastinal desmoid tumor: a case report.Mediastinum (Hong Kong, China) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Desmoid tumors (DTs), also known as aggressive fibromatosis, are rare neoplasms characterized by local invasiveness and a high risk of recurrence, despite their lack of metastatic potential. The management of these tumors remains challenging due to their unpredictable behavior and heterogeneous presentations. In this two-part study, we first provide a comprehensive review of the scientific evidence on diagnosis and emerging therapeutic strategies for DT. In the second part, we will present a retrospective analysis of our experience at a national reference center for sarcoma treatment, focusing on diagnostic strategies, therapeutic interventions, and clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.